These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 12672176)

  • 1. Zotepine in Huntington's disease.
    Bonelli RM; Niederwieser G; Lahousen T; Hofmann P
    Hum Psychopharmacol; 2003 Apr; 18(3):227-9. PubMed ID: 12672176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.
    Zesiewicz TA; Sullivan KL; Hauser RA; Sanchez-Ramos J
    Mov Disord; 2006 Nov; 21(11):1998-2001. PubMed ID: 16941461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term effects of tetrabenazine on chorea associated with Huntington's disease.
    Kenney C; Hunter C; Davidson A; Jankovic J
    Mov Disord; 2007 Jan; 22(1):10-3. PubMed ID: 17078062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unified Huntington's disease rating scale: a follow up.
    Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
    Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
    Furr Stimming E; Claassen DO; Kayson E; Goldstein J; Mehanna R; Zhang H; Liang GS; Haubenberger D;
    Lancet Neurol; 2023 Jun; 22(6):494-504. PubMed ID: 37210099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.
    Saft C; Lauter T; Kraus PH; Przuntek H; Andrich JE
    BMC Neurol; 2006 Feb; 6():11. PubMed ID: 16507108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot study using nabilone for symptomatic treatment in Huntington's disease.
    Curtis A; Mitchell I; Patel S; Ives N; Rickards H
    Mov Disord; 2009 Nov; 24(15):2254-9. PubMed ID: 19845035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amantadine in the akinetic-rigid variant of Huntington's disease.
    Magnet MK; Bonelli RM; Kapfhammer HP
    Ann Pharmacother; 2004; 38(7-8):1194-6. PubMed ID: 15178736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A; Cadeddu F; Guidubaldi A; Piano C; Soleti F; Zinzi P; Bentivoglio AR
    Clin Neuropharmacol; 2008; 31(6):313-8. PubMed ID: 19050408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial.
    Vitale C; Marconi S; Di Maio L; De Michele G; Longo K; Bonavita V; Barone P
    Mov Disord; 2007 Dec; 22(16):2359-64. PubMed ID: 17894335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose olanzapine in Huntington's disease.
    Bonelli RM; Niederwieser G; Tribl GG; Költringer P
    Int Clin Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 11890191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A shortened version of the motor section of the Unified Huntington's Disease Rating Scale.
    Siesling S; Zwinderman AH; van Vugt JP; Kieburtz K; Roos RA
    Mov Disord; 1997 Mar; 12(2):229-34. PubMed ID: 9087982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complex movement behaviour and progression of Huntington's disease.
    Andrich J; Saft C; Ostholt N; Müller T
    Neurosci Lett; 2007 Apr; 416(3):272-4. PubMed ID: 17321683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unified Huntington's disease rating scale: clinical practice and a critical approach.
    Klempír J; Klempírova O; Spacková N; Zidovská J; Roth J
    Funct Neurol; 2006; 21(4):217-21. PubMed ID: 17367582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease.
    Reilmann R; Bohlen S; Klopstock T; Bender A; Weindl A; Saemann P; Auer DP; Ringelstein EB; Lange HW
    Mov Disord; 2010 Oct; 25(13):2195-202. PubMed ID: 20645403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
    Mov Disord; 1996 Mar; 11(2):136-42. PubMed ID: 8684382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine in Huntington's disease.
    Paleacu D; Anca M; Giladi N
    Acta Neurol Scand; 2002 Jun; 105(6):441-4. PubMed ID: 12027832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.
    van Vugt JP; Siesling S; Vergeer M; van der Velde EA; Roos RA
    J Neurol Neurosurg Psychiatry; 1997 Jul; 63(1):35-9. PubMed ID: 9221965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of tetrabenazine on gait and functional mobility in individuals with Huntington's disease.
    Kegelmeyer DA; Kloos AD; Fritz NE; Fiumedora MM; White SE; Kostyk SK
    J Neurol Sci; 2014 Dec; 347(1-2):219-23. PubMed ID: 25456459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.